Arenaria
Turnstone Biologics Discontinues Final Clinical Program, Initiates Strategic Review Amid Financial Constraints
Turnstone Biologics, TIDAL-01, clinical program discontinuation, layoffs, strategic alternatives, TIL therapy, manufacturing costs, biotech industry challenges
Turnstone Biologics Undergoes Strategic Restructuring with Layoffs and Leadership Changes
Turnstone Biologics, layoffs, leadership changes, strategic restructuring, biotech industry